Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: A pooled analysis of 1546 patients

Blood

Volumn 122, Issue 19, 2013, Pages 3251-3262

  Barta, Stefan K ^a   Xue, Xiaonan ^a   Wang, Dan ^a   Tamari, Roni ^b   Lee, Jeannette Y ^c   Mounier, Nicolas ^d   Kaplan, Lawrence D ^e   Ribera, Josep Maria ^f   Spina, Michele ^g   Tirelli, Umberto ^g   Weiss, Rudolf ^h   Galicier, Lionel ⁱ   Boue, Francois ^j   Wilson, Wyndham H ^k   Wyen, Christoph ^l   Oriol, Albert ^f   Navarro, José Tomás ^f   Dunleavy, Kieron ^k   Little, Richard F ^k   Ratner, Lee ^m   Garcia, Olga ^f   Morgades, Mireia ^f   Remick, Scot C ⁿ   Noy, Ariela ^b   Sparano, Joseph A ^a   more..

^a MONTEFIORE MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^d Groupe d'Etude des Lymphomes de l'Adulte (GELA)   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h Practice for Hematology Oncology and Infectious Diseases   (Germany)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j HÔPITAL ANTOINE BÉCLÈRE   (France)

^k NATIONAL CANCER INSTITUTE   (United States)

^l UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^m WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ WEST VIRGINIA UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TENIPOSIDE; VINCRISTINE; VINDESINE;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; FEMALE; FOLLOW UP; HIV ASSOCIATED NONHODGKIN LYMPHOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDLINE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STEM CELL TRANSPLANTATION; TELECOMMUNICATION; VIRUS LOAD;

EID: 84888214986     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-498964     Document Type: Article

References (49)

1. Coté TR, Biggar RJ, Rosenberg PS, et al; AIDS/Cancer Study Group. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. Int J Cancer. 1997;73(5):645-650.
2. Little RF, Gutierrez M, Jaffe ES, Pau A, Horne M, Wilson W. HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA. 2001;285(14):1880-1885.
3. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96(8):2730-2734.
4. Patel P, Hanson DL, Sullivan PS, et al; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148(10):728-736.
5. Bohlius J, Schmidlin K, Costagliola D, et al; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009;14(8):1065-1074.
6. Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005;143(4):265-273.
7. Mounier N, Spina M, Gisselbrecht C, Mounier N, Spina M, Gisselbrecht C. Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol. 2007;136(5):685-698.
8. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD; National Institute of Allergy and Infectious Diseases. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142-lowdose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1998;16(11):3601-3606.
9. Noy A, Noy A. Update in HIV lymphoma. Curr Opin Oncol. 2006;18(5):449-455.
10. Sparano JA. HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol. 2007;19(5):458-463.
11. Levine AM. Management of AIDS-related lymphoma. Curr Opin Oncol. 2008;20(5):522-528.
12. Oriol A, Ribera JM, Esteve J, et al; PETHEMA Group, Spanish Society of Hematology. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica. 2003;88(4):445-453.
13. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008;113(1):117-125.
14. Dunleavy K, Little R, Wayne A, et al. Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab. Infect Agent Cancer. 2009;4(Suppl 2):O9.
15. Ferreri A J M, Bruno Ventre M, Donadoni G, et al. Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. Br J Haematol. 2012;159(2):252-255.
16. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
17. Pfreundschuh M, Trümper L, Österborg A, et al; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
18. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538-1543.
19. Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012;119(14):3245-3255.
20. Mart́i-Carvajal AJ, Cardona Andrés F, Lawrence A. Interventions for previously untreated patients with AIDS-associated Non-Hodgkin's Lymphoma. Cochrane Database Syst Rev. 2009; (3): CD005419.
21. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. 0. The Cochrane Collaboration. http://www.cochrane- handbook.org. Accessed March 28, 2011.
22. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87(2):495-508.
23. Galicier L, Fieschi C, Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood. 2007;110(8):2846-2854.
24. Oksenhendler E, Gerard L, Dubreuil M-L, et al. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leuk Lymphoma. 2000;39(1-2):87-95.
25. Remick SC, McSharry JJ, Wolf BC, et al. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma. J Clin Oncol. 1993;11(9):1691-1702.
26. Agresti A. Categorical Data Analysis. New York: John Wiley; 2002.
27. Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107(10):3832-3840.
28. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
29. Ribera J-M, Wyen C, Morgades M, et al. Specific chemotherapy and rituximab in HIV-infected patients with Burkitt's leukemia or lymphoma. Results of a German-Spanish study and analysis of prognostic factors. ASH Annu Mtg Abstr. 2010;116(21):3944.
30. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017-3024.
31. Sparano JA, Lee JY, Kaplan LD, et al; AIDS Malignancy Consortium. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008-3016.
32. Ribera J-M, Oriol A, Morgades M, et al; PETHEMA, GELTAMO, GELCAB and GESIDA Groups. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140(4):411-419.
33. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(25):4123-4128.
34. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial. Cancer. 2006;106(7):1560-1568.
35. Navarro JT, Lloveras N, Ribera JM, Oriol A, Mate JL, Feliu E. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica. 2005;90(5):704-706.
36. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. [see comment] Blood. 2005;105(5):1891-1897.
37. Oriol A, Ribera JM, Brunet S, Del Potro E, Abella E, Esteve J. Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica. 2005;90(7):990-992.
38. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol. 2004;22(8):1491-1500.
39. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653-4659.
40. Ratner L, Lee J, Tang S, et al; AIDS Malignancy Consortium. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19(8):2171-2178.
41. Remick SC, Sedransk N, Haase RF, et al. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Am J Hematol. 2001;66(3):178-188.
42. Ribera JM, Garćia O, Grande C, et al. Doseintensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013;119(9):1660-1668.
43. Agency for Healthcare Research and Quality. US Preventive Services Task Force (USPSTF) Procedure Manual. Section 4: Evidence Report Development, 4.2 Critical Appraisal. US Preventive Services Task Force (USPSTF) Procedure Manual. http://www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual4.htm. Accessed September 17, 2013.
44. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685-2693.
45. El-Sadr WM, Lundgren J, Neaton JD, et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD41 count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296.
46. Manzardo C, Esteve A, Ortega N, et al. Optimal timing for initiation of highly active antiretroviral therapy in treatment-naive human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort. Clin Microbiol Infect. 2012;25(10):1469-0691.
47. Shao HJ, Crump JA, Ramadhani HO, et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res Hum Retroviruses. 2009;25(12):1277-1285.
48. Sinha S, Shekhar RC, Singh G, et al. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis. 2012;12(1):168.
49. Castillo JJ, Echenique IA. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol. 2012;87(3):330-333.